Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says

The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular diabetes treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday.

Patients taking Eli Lilly’s Mounjaro were significantly more likely to lose 5%, 10% and 15% of their body weight overall and saw larger reductions in body weight after three months, six months and a year compared with those on Novo Nordisk’s Ozempic in the study by Truveta Research. The firm compiles and analyzes patient data from a collective of health-care systems.

The results from the study, which is not yet peer-reviewed, come as both drugs and similar treatments approved for weight loss soar in demand in the U.S. for their ability to help patients shed unwanted pounds over time. Mounjaro and Ozempic are only approved for the treatment of Type 2 diabetes, but many people use the weekly injections off-label to lose weight.

A spokesperson for Eli Lilly said the company does not promote or encourage off-label use of any of its medicines and noted that the new study was not sponsored by the drugmaker.

Meanwhile, Mounjaro and another version of the drug approved for weight loss called Zepbound are the same medicine with the same dosage level, the spokesperson added. $Novo-Nordisk A/S(NVO.US)$ $Eli Lilly and Co(LLY.US)$